Early data from the LuPIN trial in men with mCRPC

A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (177Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …

ADT is associated with risk for Alzheimer’s and dementia in largest study to date

According to the newest and largest known analysis of data currently available, there is a small but statistically significant association between treatment with androgen deprivation therapy (ADT) and increase in risk for Alzheimer’s disease and/or dementia over time. … READ MORE …

Patient-reported outcomes and the management of prostate cancer

Andrew Vickers, PhD, who works at the Memorial Sloan-Kettering Cancer Center in New York, is not a physician. He is a statistician and a research methodologist. And he is a member of the Scientific Advisory Board to The “New” Prostate Cancer InfoLink. … READ MORE …

Evidence for dose escalation in adjuvant/salvage radiation

It is well known that prostate cancer is relatively radio-resistant compared to other kinds of cancer. … READ MORE …

Patient satisfaction and the management of localized prostate cancer

A recent paper from a large Swedish research group has addressed patient satisfaction and the management of localized prostate cancer — with a specific, inclusive focus on the satisfaction of men initially managed on active surveillance. … READ MORE …

Gallium-68 PSMA vs. fluorine-18 fluciclovine PET/CT scans

According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …

Data from the TAXOMET trial also presented at ASCO

Data from a small, Phase II, French trial known as the TAXOMET trial were also presented yesterday at the ASCO meeting. … READ MORE …